Effect of <i>Dendrobium officinale</i> leaf fermentation fluid on a mouse model of alcoholic hepatitis and its mechanism of action

Xingnian ZHOU; Yuhong LIU; Yujie QIN; Quan ZHANG; Mingliang CHENG; Hong LI

doi:10.12449/JCH240218

Volume 40 Issue 2

Feb. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(2): 335-342

PDF( 2486 KB)

Effect of Dendrobium officinale leaf fermentation fluid on a mouse model of alcoholic hepatitis and its mechanism of action

DOI: 10.12449/JCH240218

1.
Department of Infectious Diseases，The Affiliated Hospital of Guizhou Medical University，Guiyang 550001，China
2.
School of Clinical Medicine，Guizhou Medical University，Guiyang 550001，China

Research funding:

National Natural Science Foundation of China (82060123);

Guizhou Provincial Health Commission (gzwjk2019-1-082);

Foundation of Guizhou Science and Technology Department (［2020］1Y299);

National Nature Cultivation Project of Affiliated Hospital of Guizhou Medical University (I-2020-12);

Doctoral Foundation of Affiliated Hospital of Guizhou Medical University (gyfybsky-2021-28)

More Information

Corresponding author: LI Hong， 625062102@qq.com （ORCID： 0000-0003-0601-3198）
Received Date: 2023-05-17
Accepted Date: 2023-06-26
Published Date: 2024-02-19

Abstract

Abstract

Objective To investigate the intervention mechanism of Dendrobium officinale leaf fermentation fluid in mice with alcoholic hepatitis. Methods A total of 70 healthy male C57BL/6J mice， aged 6-8 weeks， were randomly divided into normal group， model group， liquid feed control group， silybin group， and low-， middle-， and high-dose Dendrobium officinale leaf fermentation fluid groups， with 10 mice in each group. The mice in the normal group were given normal diet， and those in the other groups were given Lieber-DeCarli classic liquid diet for 8 weeks to induce alcoholic hepatitis. During modeling， the mice in the low-， middle-， and high-dose Dendrobium officinale leaf fermentation fluid groups were given Dendrobium liquid manufactured by Warmen Pharmaceutical， and the mice in all the other groups were given pure water； the mice in the normal group， the model group， and the liquid feed control group were given normal saline by gavage， those in the silybin group were given silybin 0.25 mL/10 g by gavage， and those in the low-， middle-， and high-dose Dendrobium officinale leaf fermentation fluid groups were given Dendrobium officinale leaf fermentation fluid at a dose of 0.125 mL/10 g， 0.250 mL/10 g， and 0.375 mL/10 g， respectively， by gavage， once a day. At week 8， chloral hydrate was injected intraperitoneally for anesthesia， and blood samples were collected from the eyeball. After serum was separated， the biochemical method was used to measure the levels of aspartate aminotransferase （AST） and alanine aminotransferase （ALT）； HE staining and oil red staining were used to observe liver histopathology and lipid accumulation in mice； multiplex Luminex assay was used to measure the serum levels of interleukin-6 （IL-6）， interleukin-1β （IL-1β）， tumor necrosis factor-α （TNF-α）， and CCL2； quantitative real-time PCR， Western blot， and immunofluorescence assay were used to measure the protein expression levels of NLRP3， caspase-1， caspase-11， gasdermin D （GSDMD）， N-terminal gasdermin D （GSDMD-N） in liver tissue. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups. Results Compared with the normal group， the model group had significant increases in the serum levels of AST， ALT， IL-6， IL-1β， TNF-α， and CCL2 （all P<0.05）， and compared with the model group， the high-dose Dendrobium officinale leaf fermentation fluid group had significant reductions in the serum levels of AST， ALT， IL-6， IL-1β， TNF-α， and CCL2 （all P<0.05）. HE staining showed that the model group had disordered structure of hepatic lobules， with a large number of steatosis vacuoles and massive cell necrosis， and compared with the model group， the high-dose Dendrobium officinale leaf fermentation fluid group had alleviation of liver histopathological injury， intact structure of most hepatic lobules， and a small amount of inflammatory cell infiltration. Oil red staining showed that the model group had accumulation of large and small lipid droplets in the liver and a significant increase in liver fat content， and compared with the model group， the high-dose Dendrobium officinale leaf fermentation fluid group had significant alleviation of hepatic steatosis， with the presence of sporadic small lipid droplets. Immunofluorescence assay of liver tissue showed that compared with the normal group， the model group had a significant increase in the ratio of GSDMD-positive staining area in hepatocyte cytoplasm （P<0.001）， and compared with the model group， the high-dose Dendrobium officinale leaf fermentation fluid group had a significant reduction in such ratio in hepatocyte cytoplasm （P<0.001）. Quantitative real-time PCR showed that compared with the normal group， the model group had significant increases in the protein expression levels of NLRP3， caspase-1， caspase-11， GSDMD， GSDMD-N， interleukin-18 （IL-18）， and IL-1β in liver tissue （all P<0.05）， and compared with the model group， the high-dose Dendrobium officinale leaf fermentation fluid group had significant reductions in the protein expression levels of NLRP3， caspase-1， caspase-11， GSDMD， GSDMD-N， IL-18， and IL-1 （all P<0.05）. Compared with the model group， the high-dose Dendrobium officinale leaf fermentation fluid group had significant reductions in the protein expression levels of caspase-1 and caspase-11 （both P<0.05）， with a relative expression level of caspase-1 of 1.757 （reduced by 26.6% compared with the model group） and a relative expression level of caspase-11 of 0.455 （reduced by 70.3% compared with the model group）， suggesting that caspase-11 showed a greater reduction than caspase-1. Conclusion Dendrobium officinale leaf fermentation fluid can alleviate alcoholic hepatitis in mice， possibly by inhibiting the non-classical cell pyroptosis pathway mediated by caspase-11.
- Hepatitis， Alcoholic,
- Dendrobii Officmalis Caulis,
- Pyroptosis,
- Mice， Inbred C57BL

FullText(HTML)

References(16)

References

[1]	ALTAMIRANO J, BATALLER R. Alcoholic liver disease: Pathogenesis and new targets for therapy[J]. Nat Rev Gastroenterol Hepatol, 2011, 8( 9): 491- 501. DOI: 10.1038/nrgastro.2011.134.
[2]	SHI JJ, ZHAO Y, WANG K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526( 7575): 660- 665. DOI: 10.1038/nature15514.
[3]	LIU X, XIA SY, ZHANG ZB, et al. Channelling inflammation: Gasdermins in physiology and disease[J]. Nat Rev Drug Discov, 2021, 20( 5): 384- 405. DOI: 10.1038/s41573-021-00154-z.
[4]	AMBADE A, LOWE P, KODYS K, et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice[J]. Hepatology, 2019, 69( 3): 1105- 1121. DOI: 10.1002/hep.30249.
[5]	FENG LJ, LIU KY, QUAN HQ. Study on main composition and content determination of Dendrobium candidum[J]. Farm Prod Process, 2023( 6): 85- 87. DOI: 10.16693/j.cnki.1671-9646(X).2023.03.049. 冯柳娟, 刘凯月, 全海倩. 铁皮石斛主要成分及其含量检测方法的研究[J]. 农产品加工, 2023( 6): 85- 87. DOI: 10.16693/j.cnki.1671-9646(X).2023.03.049.
[6]	LIU YG, YANG LL, ZHANG Y, et al. Dendrobium officinale polysaccharide ameliorates diabetic hepatic glucose metabolism via glucagon-mediated signaling pathways and modifying liver-glycogen structure[J]. J Ethnopharmacol, 2020, 248: 112308. DOI: 10.1016/j.jep.2019.112308.
[7]	CHU WH, WANG P, MA Z, et al. Ultrasonic treatment of Dendrobium officinale polysaccharide enhances antioxidant and anti-inflammatory activity in a mouse D-galactose-induced aging model[J]. Food Sci Nutr, 2022, 10( 8): 2620- 2630. DOI: 10.1002/fsn3.2867.
[8]	YANG K, ZHAN LH, LU TT, et al. Dendrobium officinale polysaccharides protected against ethanol-induced acute liver injury in vivo and in vitro via the TLR4/NF-‍κB signaling pathway[J]. Cytokine, 2020, 130: 155058. DOI: 10.1016/j.cyto.2020.155058.
[9]	YUAN C, LIAN QH, NI BB, et al. Screening and bioinformatics analysis of key autophagy-related genes in alcoholic hepatitis[J]. Ogran Transplant, 2024, 15( 1): 90- 101. 袁超, 练庆海, 尼贝贝, 等. 酒精性肝炎自噬关键基因的筛选及生物信息学分析[J]. 器官移植, 2024, 15( 1): 90- 101.
[10]	XU H, XIAO P, ZHANG F, et al. Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: A systematic review and meta-analysis[J]. Liver Int, 2022, 42( 9): 1991- 1998. DOI: 10.1111/liv.15312.
[11]	SUNG H, KIM SW, HONG M, et al. Microbiota-based treatments in alcoholic liver disease[J]. World J Gastroenterol, 2016, 22( 29): 6673- 6682. DOI: 10.3748/wjg.v22.i29.6673.
[12]	YI YS. Caspase-11 non-canonical inflammasome: A critical sensor of intracellular lipopolysaccharide in macrophage-mediated inflammatory responses[J]. Immunology, 2017, 152( 2): 207- 217. DOI: 10.1111/imm.12787.
[13]	KHANOVA E, WU R, WANG W, et al. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients[J]. Hepatology, 2018, 67( 5): 1737- 1753. DOI: 10.1002/hep.29645.
[14]	HEO MJ, KIM TH, YOU JS, et al. Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression[J]. Gut, 2019, 68( 4): 708- 720. DOI: 10.1136/gutjnl-2017-315123.
[15]	WU YL, HUANG SH, HE CM, et al. Dendrobium officinale flower extraction mitigates alcohol-induced liver injury in mice: Role of antisteatosis, antioxidative, and anti-inflammatory[J]. Evid Based Complement Alternat Med, 2020, 2020: 1421853. DOI: 10.1155/2020/1421853.
[16]	YUAN HQ, LIANG CY, LIANG J, et al. Protection of Dendrobium Officinale against acute alcoholic liver injury in mice[J]. J Jinan Univ Nat Sci Med Ed, 2016, 37( 5): 384- 388. DOI: 10.11778/j.jdxb.2016.05.005. 袁慧琦, 梁楚燕, 梁健, 等. 铁皮石斛对小鼠急性酒精性肝损伤的保护作用[J]. 暨南大学学报(自然科学与医学版), 2016, 37( 5): 384- 388. DOI: 10.11778/j.jdxb.2016.05.005.

Relative Articles

[1]	Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association， Chinese Society of Liver Cancer， Liver Study Group of Surgery Committee of Beijing Medical Association， et al. Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)[J]. Journal of Clinical Hepatology, 2025, 41(1): 30-40. doi: 10.3760/cma.j.cn113884-20240814-00245
[2]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[3]	Youcheng XIE, Shun CHEN, Chuyi LI, Ying ZHENG, Dong JIA, Jiucong ZHANG, Xiaohui YU. Application of immune checkpoint inhibitors in liver transplantation for patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 941-947. doi: 10.3969/j.issn.1001-5256.2023.04.030
[4]	Shun CHEN, Youcheng XIE, Junke WANG, Baoyin ZHAO, Jiucong ZHANG, Pan WANG, Xiaohui YU. Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation[J]. Journal of Clinical Hepatology, 2023, 39(6): 1424-1430. doi: 10.3969/j.issn.1001-5256.2023.06.027
[5]	Lizhen ZHU, Xiaolei XU, ABUDUSALAMU Aini, Xiaojuan WANG, Hu ZHOU, Rui TANG, Haining FAN, Qian LU. Research advances in immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(5): 1197-1203. doi: 10.3969/j.issn.1001-5256.2023.05.031
[6]	Pengwei REN, Ying HAN, Xinmin ZHOU. Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2705-2709. doi: 10.3969/j.issn.1001-5256.2023.11.028
[7]	Yucheng HOU, Hongqiang ZHAO, Caoer DONG, Guangdong WU, Xuan TONG, Ang LI, Qian LU, Hong CHEN, Rui TANG. Research advances in immune checkpoint inhibitor-related cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(2): 463-468. doi: 10.3969/j.issn.1001-5256.2023.02.034
[8]	Jin LEI, Linzhi ZHANG, Yinying LU, Bowen CHEN, Shi ZUO. Local embolization combined with targeted comprehensive immunotherapy in treatment of sarcomatoid hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(4): 880-882. doi: 10.3969/j.issn.1001-5256.2022.04.026
[9]	Kangwei LI, Ding WEI, Ruohan ZHANG, Xiao LI, Kaishan TAO. Application of chimeric antigen receptor T-cell immunotherapy in primary liver cancer[J]. Journal of Clinical Hepatology, 2022, 38(10): 2387-2390. doi: 10.3969/j.issn.1001-5256.2022.10.036
[10]	Hanping WANG. Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures[J]. Journal of Clinical Hepatology, 2022, 38(5): 985-991. doi: 10.3969/j.issn.1001-5256.2022.05.003
[11]	Guoming SHI, Yanzhi PEI, Pinxiang LU, Jun CAO, Jian ZHOU, Jia FAN. Immune checkpoint inhibitors for treatment of biliary malignant tumors[J]. Journal of Clinical Hepatology, 2022, 38(5): 998-1001. doi: 10.3969/j.issn.1001-5256.2022.05.005
[12]	Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 992-997. doi: 10.3969/j.issn.1001-5256.2022.05.004
[13]	Dan LIU, Tiantian YAO, Yuhan ZHANG, Guiqiang WANG, Yan WANG. Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(11): 2457-2461. doi: 10.3969/j.issn.1001-5256.2022.11.005
[14]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[15]	Jingzhong OUYANG, Yanzhao ZHOU, Ruili ZHU, Zhengzheng WANG, Xun CHEN, Jinxue ZHOU, Qingjun LI. Application of combined therapy with molecular-targeted drugs and immune checkpoint inhibitors and other combined therapies in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(4): 925-930. doi: 10.3969/j.issn.1001-5256.2021.04.043
[16]	Zhaoyue WANG, Lai WEI, Yuan HUANG. Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 437-443. doi: 10.3969/j.issn.1001-5256.2021.02.040
[17]	Sun Tao, Ren YanQiao, Cao YanYan, Zheng ChuanSheng. Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1386-1388. doi: 10.3969/j.issn.1001-5256.2020.06.043
[18]	Wei JianYing, Sun Wei, Liu XiaoMin, Chen JingLong. Advances in targeted therapy and immunotherapy for hepatocelluar carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2320-2324. doi: 10.3969/j.issn.1001-5256.2020.10.035
[19]	Luo Kui, Sun Hang, Wu ChuanXin. Immunotherapy for biliary tract cancer: Current status and perspectives[J]. Journal of Clinical Hepatology, 2019, 35(12): 2837-2840. doi: 10.3969/j.issn.1001-5256.2019.12.043

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(8) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (657) PDF downloads(65)

Effect of Dendrobium officinale leaf fermentation fluid on a mouse model of alcoholic hepatitis and its mechanism of action

DOI: 10.12449/JCH240218

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of Dendrobium officinale leaf fermentation fluid on a mouse model of alcoholic hepatitis and its mechanism of action

DOI: 10.12449/JCH240218

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content